Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 May;88(1):141–148. doi: 10.1111/j.1476-5381.1986.tb09480.x

A protective effect of sulphinpyrazone against coronary occlusion-induced shortening of myocardial refractory periods in the rat.

B J Northover
PMCID: PMC1917107  PMID: 3708212

Abstract

The hearts of anaesthetized, artificially ventilated rats were exposed, and the left coronary artery occluded. The diastolic threshold voltage for stimulation (DTV), the duration of the bipolar electrogram (DBE) and the functional refractory period (FRP) of the ischaemic area were measured at minute intervals for an hour after occlusion. Coronary occlusion caused a rise in DTV, a prolongation of the DBE and a biphasic change in the FRP, with an initial prolongation phase (1-4 min) followed by a decline to below pre-occlusion values (5-15 min). Episodes of ventricular tachyarrhythmia (VT) were most frequent during the period 5-15 min after the onset of occlusion of the coronary artery. This coincided with the period when FRP was minimal and the difference between DBE and FRP was maximal. Pretreatment of rats with sulphinpyrazone (2.5-40 mg kg-1) or indomethacin (5-20 mg kg-1) protected against the episodes of coronary occlusion-induced VT and against the associated decline in FRP of the ischaemic muscle. Sulphinpyrazone was more effective than indomethacin in this respect and a combination of the two drugs was approximately as effective as sulphinpyrazone alone. It was concluded that sulphinpyrazone protects rats against coronary occlusion-induced episodes of VT by reducing the risk of ventricular action potential re-entry. This effect is probably due to protection against the ischaemia-induced shortening of the myocardial FRP.

Full text

PDF
147

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BROOKS C. M., GILBERT J. L., GREENSPAN M. E., LANGE G., MAZZELLA H. M. Excitability and electrical response of ischemic heart muscle. Am J Physiol. 1960 Jun;198:1143–1147. doi: 10.1152/ajplegacy.1960.198.6.1143. [DOI] [PubMed] [Google Scholar]
  2. Batsford W. P., Cannom D. S., Zaret B. L. Relations between ventricular refractoriness and regional myocardial blood flow after acute coronary occlusion. Am J Cardiol. 1978 May 22;41(6):1083–1088. doi: 10.1016/0002-9149(78)90861-5. [DOI] [PubMed] [Google Scholar]
  3. Benditt D. G., Grant A. O., Hutchison A. B., Strauss H. C. Electrophysiological effects of sulfinpyrazone on canine cardiac Purkinje fibers. Can J Physiol Pharmacol. 1980 Jun;58(6):738–742. doi: 10.1139/y80-117. [DOI] [PubMed] [Google Scholar]
  4. Bissett J. K., Watson J. W., Scovil J. A., Schmidt N., McConnell J. R., Kane J. Changes in myocardial refractory periods following ischemia in the porcine heart. J Electrocardiol. 1979 Jan;12(1):35–40. doi: 10.1016/s0022-0736(79)80042-4. [DOI] [PubMed] [Google Scholar]
  5. Boineau J. P., Cox J. L. Slow ventricular activation in acute myocardial infarction. A source of re-entrant premature ventricular contractions. Circulation. 1973 Oct;48(4):702–713. doi: 10.1161/01.cir.48.4.702. [DOI] [PubMed] [Google Scholar]
  6. Bolli R., Goldstein R. E., Davenport N., Epstein S. E. Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol. 1981 Apr;47(4):841–847. doi: 10.1016/0002-9149(81)90183-1. [DOI] [PubMed] [Google Scholar]
  7. Brunner L., Stepanek J., Brunner H. Reduction of mortality by sulphinpyrazone after experimental myocardial infarction in the rat. J Pharm Pharmacol. 1980 Oct;32(10):714–715. doi: 10.1111/j.2042-7158.1980.tb13047.x. [DOI] [PubMed] [Google Scholar]
  8. Davenport N., Goldstein R. E., Capurro N., Lipson L. C., Bonow R. O., Shulman N. R., Epstein S. E. Sulfinpyrazone and aspirin increase epicardial coronary collateral flow in dogs. Am J Cardiol. 1981 Apr;47(4):848–854. doi: 10.1016/0002-9149(81)90184-3. [DOI] [PubMed] [Google Scholar]
  9. Downar E., Janse M. J., Durrer D. The effect of acute coronary artery occlusion on subepicardial transmembrane potentials in the intact porcine heart. Circulation. 1977 Aug;56(2):217–224. doi: 10.1161/01.cir.56.2.217. [DOI] [PubMed] [Google Scholar]
  10. Elharrar V., Foster P. R., Jirak T. L., Gaum W. E., Zipes D. P. Alterations in canine myocardial excitability during ischemia. Circ Res. 1977 Jan;40(1):98–105. doi: 10.1161/01.res.40.1.98. [DOI] [PubMed] [Google Scholar]
  11. Elharrar V., Zipes D. P. Cardiac electrophysiologic alterations during myocardial ischemia. Am J Physiol. 1977 Sep;233(3):H329–H345. doi: 10.1152/ajpheart.1977.233.3.H329. [DOI] [PubMed] [Google Scholar]
  12. Hope R. R., Lazzara R., Scherlag B. J. The induction of ventricular arrhythmias in acute myocardial ischemia by atrial pacing with long-short cycle sequences. Chest. 1977 May;71(5):651–658. doi: 10.1378/chest.71.5.651. [DOI] [PubMed] [Google Scholar]
  13. Horacek T., Neumann M., von Mutius S., Budden M., Meesmann W. Nonhomogeneous electrophysiological changes and the bimodal distribution of early ventricular arrhythmias during acute coronary artery occlusion. Basic Res Cardiol. 1984 Nov-Dec;79(6):649–667. doi: 10.1007/BF01908383. [DOI] [PubMed] [Google Scholar]
  14. Innes I. R., Weisman H. Reduction in the severity of myocardial infarction by sulfinpyrazone. Am Heart J. 1981 Aug;102(2):153–157. doi: 10.1016/s0002-8703(81)80002-6. [DOI] [PubMed] [Google Scholar]
  15. Inoue F., MacLeod B. A., Walker M. J. Intracellular potential changes following coronary occlusion in isolated perfused rat hearts. Can J Physiol Pharmacol. 1984 Jun;62(6):658–664. doi: 10.1139/y84-108. [DOI] [PubMed] [Google Scholar]
  16. Janse M. J., van Capelle F. J., Morsink H., Kléber A. G., Wilms-Schopman F., Cardinal R., d'Alnoncourt C. N., Durrer D. Flow of "injury" current and patterns of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts. Evidence for two different arrhythmogenic mechanisms. Circ Res. 1980 Aug;47(2):151–165. doi: 10.1161/01.res.47.2.151. [DOI] [PubMed] [Google Scholar]
  17. Kaplinsky E., Ogawa S., Balke C. W., Dreifus L. S. Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circulation. 1979 Aug;60(2):397–403. doi: 10.1161/01.cir.60.2.397. [DOI] [PubMed] [Google Scholar]
  18. Kaplinsky E., Ogawa S., Kmetzo J., Balke C. W., Dreifus L. S. Intramyocardial activation in early ventricular arrhythmias following coronary artery ligation. J Electrocardiol. 1980;13(1):1–6. doi: 10.1016/s0022-0736(80)80002-1. [DOI] [PubMed] [Google Scholar]
  19. Kaplinsky E., Ogawa S., Kmetzo J., Dreifus L. S. Origin of so-called right and left ventricular arrhythmias in acute myocardial ischemia. Am J Cardiol. 1978 Nov;42(5):774–780. doi: 10.1016/0002-9149(78)90097-8. [DOI] [PubMed] [Google Scholar]
  20. Karmazyn M. A direct protective effect of sulphinpyrazone on ischaemic and reperfused rat hearts. Br J Pharmacol. 1984 Sep;83(1):221–226. doi: 10.1111/j.1476-5381.1984.tb10138.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Karmazyn M., Beamish R. E., Fliegel L., Dhalla N. S. Adrenochrome-induced coronary artery constriction in the rat heart. J Pharmacol Exp Ther. 1981 Oct;219(1):225–230. [PubMed] [Google Scholar]
  22. Kristiansen O., Refsum H., Hotvedt R. Electrophysiological and mechanical effects of sulphinpyrazone on isolated rat atria. Clin Physiol. 1982 Aug;2(4):299–306. doi: 10.1111/j.1475-097x.1982.tb00034.x. [DOI] [PubMed] [Google Scholar]
  23. Lazzara R., El-Sherif N., Hope R. R., Scherlag B. J. Ventricular arrhythmias and electrophysiological consequences of myocardial ischemia and infarction. Circ Res. 1978 Jun;42(6):740–749. doi: 10.1161/01.res.42.6.740. [DOI] [PubMed] [Google Scholar]
  24. Leprán I., Koltai M., Szekeres L. Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats. Eur J Pharmacol. 1981 Jan 16;69(2):235–238. doi: 10.1016/0014-2999(81)90422-2. [DOI] [PubMed] [Google Scholar]
  25. Levine H. J., Avitall B., Pauker S. G., Naimi S. Sequential unipolar strength-interval curves and conduction times during myocardial ischemia and reperfusion in the dog. Circ Res. 1978 Jul;43(1):63–72. doi: 10.1161/01.res.43.1.63. [DOI] [PubMed] [Google Scholar]
  26. Levites R., Anderson G. J. Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia. Am Heart J. 1979 Sep;98(3):339–344. doi: 10.1016/0002-8703(79)90046-2. [DOI] [PubMed] [Google Scholar]
  27. Levites R., Banka V. S., Helfant R. H. Electrophysiologic effects of coronary occlusion and reperfusion. Observations of dispersion of refractoriness and ventricular automaticity. Circulation. 1975 Nov;52(5):760–765. doi: 10.1161/01.cir.52.5.760. [DOI] [PubMed] [Google Scholar]
  28. Livio M., Villa S., de Gaetano G. Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulphinpyrazone administration to rats. J Pharm Pharmacol. 1980 Oct;32(10):718–719. doi: 10.1111/j.2042-7158.1980.tb13049.x. [DOI] [PubMed] [Google Scholar]
  29. Maclean D., Fishbein M. C., Braunwald E., Maroko P. R. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J Clin Invest. 1978 Mar;61(3):541–551. doi: 10.1172/JCI108965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mertz T. E., Kaplan H. R. Pirmenol hydrochloride (CI-845) and reference antiarrhythmic agents: effects on early ventricular arrhythmias after acute coronary artery ligation in anesthetized rats. J Pharmacol Exp Ther. 1982 Nov;223(2):580–586. [PubMed] [Google Scholar]
  31. Moschos C. B., Escobinas A. J., Jorgensen O. B., Jr, Regan T. J. Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. Circulation. 1981 Jul;64(1):13–18. doi: 10.1161/01.cir.64.1.13. [DOI] [PubMed] [Google Scholar]
  32. Northover B. J. A comparison of the effects of bethanidine, meobentine and quinidine on the electrical activity of rat hearts in vivo and in vitro. Br J Pharmacol. 1985 Mar;84(3):755–763. doi: 10.1111/j.1476-5381.1985.tb16158.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pedersen A. K., FitzGerald G. A. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther. 1985 Jan;37(1):36–42. doi: 10.1038/clpt.1985.8. [DOI] [PubMed] [Google Scholar]
  34. Ruffy R., Lovelace D. E., Mueller T. M., Knoebel S. B., Zipes D. P. Relationship between changes in left ventricular bipolar electrograms and regional myocardial blood flow during acute coronary artery occlusion in the dog. Circ Res. 1979 Dec;45(6):764–770. doi: 10.1161/01.res.45.6.764. [DOI] [PubMed] [Google Scholar]
  35. Russell D. C., Smith J. H., Oliver M. F. Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischaemia in the dog. Br Heart J. 1979 Jul;42(1):88–96. doi: 10.1136/hrt.42.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Scherlag B. J., el-Sherif N., Hope R., Lazzara R. Characterization and localization of ventricular arrhythmias resulting from myocardial ischemia and infarction. Circ Res. 1974 Sep;35(3):372–383. doi: 10.1161/01.res.35.3.372. [DOI] [PubMed] [Google Scholar]
  37. Stewart J. R., Burmeister W. E., Burmeister J., Lucchesi B. R. Electrophysiologic and antiarrhythmic effects of phentolamine in experimental coronary artery occlusion and reperfusion in the dog. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):77–91. doi: 10.1097/00005344-198001000-00009. [DOI] [PubMed] [Google Scholar]
  38. Stäubli R. C., Baur H. R., Althaus U., Pop H. P., Wehrli H. P., Gurtner H. P. Influence of sulfinpyrazone on infarct size, hemodynamics, and arrhythmia following coronary occlusion in the pig. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):829–832. doi: 10.1097/00005344-198409000-00014. [DOI] [PubMed] [Google Scholar]
  39. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial. N Engl J Med. 1978 Feb 9;298(6):289–295. doi: 10.1056/NEJM197802092980601. [DOI] [PubMed] [Google Scholar]
  40. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group. N Engl J Med. 1980 Jan 31;302(5):250–256. doi: 10.1056/NEJM198001313020502. [DOI] [PubMed] [Google Scholar]
  41. The Anturane Reinfarction Trial: reevaluation of outcome. N Engl J Med. 1982 Apr 22;306(16):1005–1008. doi: 10.1056/NEJM198204223061640. [DOI] [PubMed] [Google Scholar]
  42. Wyse D. G. Dose-related cardiac electrophysiologic effects of sulfinpyrazone. Clin Pharmacol Ther. 1985 Feb;37(2):166–173. doi: 10.1038/clpt.1985.30. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES